Scinai Immunotherapeutics' PC111 featured in peer-reviewed publication
PC111 Development: Scinai Immunotherapeutics published a peer-reviewed article confirming the efficacy of PC111, a human anti-Fas Ligand monoclonal antibody, in preventing blister formation in pemphigus and potentially treating SJS/TEN, with a non-immunosuppressive action at the keratinocyte level.
Market Potential and Funding: The combined market opportunity for these conditions exceeds $1B, and Scinai plans to advance PC111 through clinical development, supported by a potential EUR15M grant for IND readiness, with accelerated approval pathways being explored for market entry within three to four years.
Trade with 70% Backtested Accuracy
Analyst Views on SCNI
About SCNI
About the author
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai's CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week in Tel Aviv, focusing on Israel's biopharma manufacturing capabilities and their impact on the industry, particularly in early development and clinical manufacturing.
- Manufacturing Capability Assessment: The roundtable will examine the current state of Israel's biopharma development ecosystem, emphasizing GMP manufacturing for clinical supply amidst increasing global complexity in biopharma manufacturing, highlighting the need for enhanced local capabilities.
- Diverse Participation: Representatives from government, public agencies, international biopharma manufacturers, and investors are expected to participate, fostering in-depth dialogue and collaboration on the future development of Israel's biopharma sector.
- Strategic Importance: By discussing the infrastructure and manufacturing capabilities in Israel's biopharma sector, the roundtable aims to provide practical insights that will help companies maintain competitiveness and attract investment over the next 5-10 years.
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai Immunotherapeutics CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week at Expo Tel Aviv, aimed at facilitating a realistic discussion on Israel's biopharma development and manufacturing ecosystem.
- Infrastructure Assessment: The roundtable will focus on early-stage development, CMC activities, and clinical manufacturing infrastructure, emphasizing laboratory access, CMC and analytical capabilities, and GMP manufacturing for clinical supply, which are foundational for efficient development and regulatory readiness.
- Global Trends Analysis: The discussion will consider global trends shaping biopharma manufacturing, including increasing complexity of biologic modalities and evolving regulatory expectations, helping participants understand how Israel's competitiveness in biopharma may evolve over the next 5-10 years.
- Diverse Participation: Representatives from government, public agencies, Israeli and international biopharma manufacturers, and CDMOs are expected to participate, reflecting the industry's emphasis on the importance of biopharma manufacturing infrastructure and collaboration needs.
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
Research Validation: Scinai Immunotherapeutics announced new peer-reviewed findings confirming the efficacy and safety of PC111, a human anti-Fas Ligand monoclonal antibody, in treating pemphigus and potentially SJS/TEN, demonstrating its ability to prevent blister formation without immunosuppression.
Market Potential and Development Plans: The company aims to advance PC111 through clinical development with an expected market opportunity exceeding one billion dollars, leveraging orphan drug designation and exploring accelerated approval pathways for faster market entry.
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Celestica's Financial Performance: Celestica Inc. shares surged 12.1% in pre-market trading after reporting second-quarter earnings of $1.39 per share, exceeding analyst expectations, and raising its FY25 guidance along with third-quarter estimates.
Market Movements: Several stocks experienced significant pre-market trading movements, with Salarius Pharmaceuticals gaining 279.1%, while AIM ImmunoTech saw a decline of 40.9% following disappointing trial data.
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
Recognition of Dr. Roberta Lotti: Dr. Roberta Lotti from Pincell Srl received the "Oscar of Italian Dermatology" for her research on PC111, an innovative anti-Fas Ligand monoclonal antibody targeting autoimmune diseases like Pemphigus Vulgaris, highlighting its potential to transform treatment approaches.
Strategic Partnership and Future Plans: Scinai Immunotherapeutics is reinforcing its strategic option agreement to acquire Pincell, emphasizing the clinical relevance of PC111 and its promising non-immunosuppressive mechanism, which could provide significant benefits over existing therapies for severe skin conditions.
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
CEO Participation in Conference: Scinai Immunotherapeutics CEO Amir Reichman will attend the BIO International Convention 2025 to meet with investors, pharma partners, and CDMO clients, showcasing the company's recent advancements and seeking new collaborations.
Financial Growth and Cost Optimization: Scinai raised $1.38 million through a Standby Equity Purchase Agreement, enhancing its operational flexibility while implementing cost-reduction measures to lower expenses by approximately $815,000, aiming for financial stability and growth in its CDMO business.
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai's CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week in Tel Aviv, focusing on Israel's biopharma manufacturing capabilities and their impact on the industry, particularly in early development and clinical manufacturing.
- Manufacturing Capability Assessment: The roundtable will examine the current state of Israel's biopharma development ecosystem, emphasizing GMP manufacturing for clinical supply amidst increasing global complexity in biopharma manufacturing, highlighting the need for enhanced local capabilities.
- Diverse Participation: Representatives from government, public agencies, international biopharma manufacturers, and investors are expected to participate, fostering in-depth dialogue and collaboration on the future development of Israel's biopharma sector.
- Strategic Importance: By discussing the infrastructure and manufacturing capabilities in Israel's biopharma sector, the roundtable aims to provide practical insights that will help companies maintain competitiveness and attract investment over the next 5-10 years.
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai Immunotherapeutics CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week at Expo Tel Aviv, aimed at facilitating a realistic discussion on Israel's biopharma development and manufacturing ecosystem.
- Infrastructure Assessment: The roundtable will focus on early-stage development, CMC activities, and clinical manufacturing infrastructure, emphasizing laboratory access, CMC and analytical capabilities, and GMP manufacturing for clinical supply, which are foundational for efficient development and regulatory readiness.
- Global Trends Analysis: The discussion will consider global trends shaping biopharma manufacturing, including increasing complexity of biologic modalities and evolving regulatory expectations, helping participants understand how Israel's competitiveness in biopharma may evolve over the next 5-10 years.
- Diverse Participation: Representatives from government, public agencies, Israeli and international biopharma manufacturers, and CDMOs are expected to participate, reflecting the industry's emphasis on the importance of biopharma manufacturing infrastructure and collaboration needs.
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
Research Validation: Scinai Immunotherapeutics announced new peer-reviewed findings confirming the efficacy and safety of PC111, a human anti-Fas Ligand monoclonal antibody, in treating pemphigus and potentially SJS/TEN, demonstrating its ability to prevent blister formation without immunosuppression.
Market Potential and Development Plans: The company aims to advance PC111 through clinical development with an expected market opportunity exceeding one billion dollars, leveraging orphan drug designation and exploring accelerated approval pathways for faster market entry.
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Celestica's Financial Performance: Celestica Inc. shares surged 12.1% in pre-market trading after reporting second-quarter earnings of $1.39 per share, exceeding analyst expectations, and raising its FY25 guidance along with third-quarter estimates.
Market Movements: Several stocks experienced significant pre-market trading movements, with Salarius Pharmaceuticals gaining 279.1%, while AIM ImmunoTech saw a decline of 40.9% following disappointing trial data.
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
Recognition of Dr. Roberta Lotti: Dr. Roberta Lotti from Pincell Srl received the "Oscar of Italian Dermatology" for her research on PC111, an innovative anti-Fas Ligand monoclonal antibody targeting autoimmune diseases like Pemphigus Vulgaris, highlighting its potential to transform treatment approaches.
Strategic Partnership and Future Plans: Scinai Immunotherapeutics is reinforcing its strategic option agreement to acquire Pincell, emphasizing the clinical relevance of PC111 and its promising non-immunosuppressive mechanism, which could provide significant benefits over existing therapies for severe skin conditions.
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
CEO Participation in Conference: Scinai Immunotherapeutics CEO Amir Reichman will attend the BIO International Convention 2025 to meet with investors, pharma partners, and CDMO clients, showcasing the company's recent advancements and seeking new collaborations.
Financial Growth and Cost Optimization: Scinai raised $1.38 million through a Standby Equity Purchase Agreement, enhancing its operational flexibility while implementing cost-reduction measures to lower expenses by approximately $815,000, aiming for financial stability and growth in its CDMO business.
